AdvanDx

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens causing critical infections in hospitalized patients. Our mission is to help healthcare providers optimize antibiotic therapy earlier in order to improve patient outcomes while limiting unnecessary antibiotic use and reducing hospital costs.

AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for species, resistance and virulence marker identification of bacterial cells found in samples from patients with critical infections.